Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in Nonalcoholic Steatohepatitis (NASH)
NCT00063232Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jun 2003
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liquid metformin (Aspargo Labs) in Nonalcoholic steatohepatitis (NASH), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Change in the Histological NASH Activity Index at 48 weeks. Started Jun 2003; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT00063232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063232.